Instem plc Exercise of Options, Issue of Equity & TVR (5644H)

TIDMINS

RNS Number : 5644H

Instem plc

28 July 2023

Instem plc

("Instem", the "Group" or the "Company")

Exercise of Options, Issue of Equity & Total Voting Rights

Instem plc (AIM: INS), a leading p rovider of IT solutions to the global life sciences market, confirms that it has issued, conditional on admission, 10,000 ordinary shares ("New Ordinary Shares"), pursuant to an exercise of share options by an employee of the Company on 27 July 2023.

Issue of Equity and Admission

Application will be made to the London Stock Exchange for the admission of the 10,000 New Ordinary Shares to trading on AIM. Admission is expected to take place at 8.00 a.m. on 02 August 2023.

Total voting rights

Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 22,899,433 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 22,899,433.

The figure of 22,899,433 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 
 For further information, please contact: 
   Instem plc                               Via Walbrook 
   Phil Reason, CEO 
   Nigel Goldsmith, CFO 
 
   Singer Capital Markets (Nominated 
    Adviser & Broker)                       +44 (0) 20 7496 3000 
   Peter Steel 
    Alex Bond 
 
   Stifel Nicolaus Europe Limited (Joint 
    Broker)                                 +44 (0) 20 7710 7600 
   Ben Maddison 
   Alex Price 
    Richard Short 
 
   Walbrook Financial PR                    +44 (0) 20 7933 8780 
   Tom Cooper                               instem@walbrookpr.com 
   Nick Rome 
    Joe Walker

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

   To learn more about Instem solutions and its mission, please visit   www.instem.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCNKFBPFBKKBOB

(END) Dow Jones Newswires

July 28, 2023 05:00 ET (09:00 GMT)

Instem (LSE:INS)
Historical Stock Chart
From May 2024 to Jun 2024